Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aprocitentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 17/20 | 1.00 |
| ▸ | EDNRB known ✓ | P24530 | 16/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.71 |
| ▸ | TSPO | P30536 | 1/20 | 0.71 |
| ▸ | DRD3 | P35462 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aprocitentan SCHEMBL3646065 | 1.00 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL25646617 | 0.93 | EDNRB (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL3650930 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5101990 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL31266904 | 0.89 | EDNRA (0.80) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5500351 | 0.88 | EDNRA (0.86) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL9891388 | 0.87 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL31442652 | 0.86 | EDNRA (0.76) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL17582648 | 0.85 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 | |
| SCHEMBL5494210 | 0.85 | EDNRA (1.00) | EDNRAEDNRBSLC6A2TSPODRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119255985-A | Crystalline forms of sodium (5- (4-bromophenyl) -6- (2- ((5-bromopyrimidin-2-yl) oxy) ethoxy) pyrimidin-4-yl) (sulfamoyl) amide | 爱杜西亚药品有限公司 | 2025-01-03 | — | — | CN | claimed |
| EP-4014976-B1 | APROCITENTAN FOR USE IN THE TREATMENT OF HYPERTENSION AND RELATED DISEASES IN COMBINATION WITH VALSARTAN | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-04 | — | — | EP | claimed |
| WO-2025102245-A1 | SYNTHESIS METHOD FOR DUAL ENDOTHELIN RECEPTOR ANTAGONIST APROCITENTAN | 浙江天宇药业股份有限公司 | 2025-05-22 | — | — | WO | disclosed |
| EP-4532472-A1 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | Idorsia Pharmaceuticals Ltd (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-119255805-A | Can be used for treating hypertension Alpraxitanum of (C) | 爱杜西亚药品有限公司 | 2025-01-03 | — | — | CN | disclosed |
| EP-4014976-B1 | APROCITENTAN FOR USE IN THE TREATMENT OF HYPERTENSION AND RELATED DISEASES IN COMBINATION WITH VALSARTAN | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-09-04 | — | — | EP | disclosed |
| CN-117736152-A | Synthesis method of dual endothelin receptor antagonist apixitan | 浙江天宇药业股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023227721-A1 | CRYSTALLINE FORMS OF SODIUM (5-(4-BROMOPHENYL)-6-(2-((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)(SULFAMOYL)AMIDE | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023111797-A1 | PYRIMIDINE SULFAMIDE DERIVATIVES AND PROCESS FOR MANUFACTURING THEM | JANSSEN BIOTECH, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-4153574-A1 | SOLID STATE FORMS OF APROCITENTAN AND PROCESS FOR PREPARATION THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2023-03-29 | — | — | EP | disclosed |